Pfizer Q3 revenue $22.6B (-6% YoY); Adj. EPS $1.78 (+40%); raises FY2022 guidance

PFIZER INC

2022-Q3 EPS reported $4.60 revenue$76,040,000,000

Reported diluted EPS $1.51 (+6%); Adjusted diluted EPS $1.78 (+40%) YoY.
Paxlovid contributed $7.5B in Q3; Comirnaty revenue guidance raised to ~$34B for 2022.
FY2022 revenue guidance raised to $99.5-102.0B; Adj. EPS guidance raised to $6.40-6.50.
Completed Biohaven ($12.8B) and GBT ($5.6B) acquisitions early Q4 2022.
Positive Phase 3 readouts for RSV vaccine, Prevnar 20 in pediatrics, and Talzenna/Xtandi combo.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

PFIZER INC reported the third quarter of 2022 results: revenue $22,638, net income 8,608, EPS $1.51. Guidance raised.

Period: the third quarter of 2022
Revenue: $22,638
Net income: 8,608
EPS: $1.51
Guidance: raised
Result: reported results

Exact text from the filing

months of 2022 and 2021 (5) are summarized below. OVERALL RESULTS ($ in millions, except per share amounts) Third-Quarter Nine Months 2022 2021 Change 2022 2021 Change Revenues $ 22,638 $ 24,035 (6%) $ 76,040 $ 57,450 32% Reported Net Income (2) 8,608 8,146 6% 26,378 18,586 42% Reported Diluted EPS (2) 1.51 1.42 6% 4.60 3.27 41% Adjusted Income (3) 10,172 7,279

View on SEC.gov

Browse all earnings releases →

PFIZER INC filing history →

Source: SEC EDGAR

accession 0000078003-22-000098

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.